These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 11309331)
1. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Ino Y; Betensky RA; Zlatescu MC; Sasaki H; Macdonald DR; Stemmer-Rachamimov AO; Ramsay DA; Cairncross JG; Louis DN Clin Cancer Res; 2001 Apr; 7(4):839-45. PubMed ID: 11309331 [TBL] [Abstract][Full Text] [Related]
2. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179 [TBL] [Abstract][Full Text] [Related]
3. Correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p. Hashimoto N; Murakami M; Takahashi Y; Fujimoto M; Inazawa J; Mineura K Cancer; 2003 May; 97(9):2254-61. PubMed ID: 12712480 [TBL] [Abstract][Full Text] [Related]
4. Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? Weller M; Berger H; Hartmann C; Schramm J; Westphal M; Simon M; Goldbrunner R; Krex D; Steinbach JP; Ostertag CB; Loeffler M; Pietsch T; von Deimling A; Clin Cancer Res; 2007 Dec; 13(23):6933-7. PubMed ID: 18056167 [TBL] [Abstract][Full Text] [Related]
5. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. van den Bent MJ; Looijenga LH; Langenberg K; Dinjens W; Graveland W; Uytdewilligen L; Sillevis Smitt PA; Jenkins RB; Kros JM Cancer; 2003 Mar; 97(5):1276-84. PubMed ID: 12599236 [TBL] [Abstract][Full Text] [Related]
6. Gene expression profiles associated with treatment response in oligodendrogliomas. French PJ; Swagemakers SM; Nagel JH; Kouwenhoven MC; Brouwer E; van der Spek P; Luider TM; Kros JM; van den Bent MJ; Sillevis Smitt PA Cancer Res; 2005 Dec; 65(24):11335-44. PubMed ID: 16357140 [TBL] [Abstract][Full Text] [Related]
7. Is the 1p/19q deletion a diagnostic marker of oligodendrogliomas? Gadji M; Fortin D; Tsanaclis AM; Drouin R Cancer Genet Cytogenet; 2009 Oct; 194(1):12-22. PubMed ID: 19737649 [TBL] [Abstract][Full Text] [Related]
8. Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Zlatescu MC; TehraniYazdi A; Sasaki H; Megyesi JF; Betensky RA; Louis DN; Cairncross JG Cancer Res; 2001 Sep; 61(18):6713-5. PubMed ID: 11559541 [TBL] [Abstract][Full Text] [Related]
9. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. McDonald JM; See SJ; Tremont IW; Colman H; Gilbert MR; Groves M; Burger PC; Louis DN; Giannini C; Fuller G; Passe S; Blair H; Jenkins RB; Yang H; Ledoux A; Aaron J; Tipnis U; Zhang W; Hess K; Aldape K Cancer; 2005 Oct; 104(7):1468-77. PubMed ID: 16088966 [TBL] [Abstract][Full Text] [Related]
10. Chromosome 1p and 19q evaluation in low-grade oligodendrogliomas: a descriptive study. Molinari C; Iorio P; Medri L; Ballardini M; Guiducci G; Cremonini AM; Cerasoli S; Riccioni L; Faedi M; Mariani GA; Zoli W; Silvestrini R; Calistri D Int J Mol Med; 2010 Jan; 25(1):145-51. PubMed ID: 19956913 [TBL] [Abstract][Full Text] [Related]
11. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. Cairncross JG; Ueki K; Zlatescu MC; Lisle DK; Finkelstein DM; Hammond RR; Silver JS; Stark PC; Macdonald DR; Ino Y; Ramsay DA; Louis DN J Natl Cancer Inst; 1998 Oct; 90(19):1473-9. PubMed ID: 9776413 [TBL] [Abstract][Full Text] [Related]
12. Anaplastic oligodendroglial tumors harboring 1p/19q deletion can be successfully treated without radiotherapy. Iwadate Y; Matsutani T; Shinozaki N; Saeki N Anticancer Res; 2011 Dec; 31(12):4475-9. PubMed ID: 22199318 [TBL] [Abstract][Full Text] [Related]
13. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Stege EM; Kros JM; de Bruin HG; Enting RH; van Heuvel I; Looijenga LH; van der Rijt CD; Smitt PA; van den Bent MJ Cancer; 2005 Feb; 103(4):802-9. PubMed ID: 15637687 [TBL] [Abstract][Full Text] [Related]
14. Losses of chromosomes 1p and 19q are rare in pediatric oligodendrogliomas. Kreiger PA; Okada Y; Simon S; Rorke LB; Louis DN; Golden JA Acta Neuropathol; 2005 Apr; 109(4):387-92. PubMed ID: 15739101 [TBL] [Abstract][Full Text] [Related]
15. Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas. Watanabe T; Nakamura M; Kros JM; Burkhard C; Yonekawa Y; Kleihues P; Ohgaki H Acta Neuropathol; 2002 Mar; 103(3):267-75. PubMed ID: 11907807 [TBL] [Abstract][Full Text] [Related]
17. Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma. Cairncross G; Jenkins R Cancer J; 2008; 14(6):352-7. PubMed ID: 19060598 [TBL] [Abstract][Full Text] [Related]
18. [Diagnostic and prognostic values of 1p and 19q deletions in adult gliomas: critical review of the literature and implications in daily clinical practice]. Fontaine D; Vandenbos F; Lebrun C; Paquis V; Frenay M Rev Neurol (Paris); 2008; 164(6-7):595-604. PubMed ID: 18565359 [TBL] [Abstract][Full Text] [Related]
19. Molecular analysis of chromosome 1, 10 and 19 abnormalities in human oligodendroglial tumors: relationship between frequency of LOH grade, age and gender. Gresner SM; Rieske P; Wozniak K; Piaskowski S; Jaskolski DJ; Skowronski W; Golanska E; Sikorska B; Liberski PP Clin Neuropathol; 2006; 25(1):18-24. PubMed ID: 16465770 [TBL] [Abstract][Full Text] [Related]